Related Experiment Video
Updated: Jun 10, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Neurotrophic factor delivery as a protective treatment for glaucoma
Thomas V Johnson1, Natalie D Bull, Keith R Martin
1Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK.
Experimental Eye Research
|August 6, 2010
Summary
Neurotrophic factors (NTFs) may protect against glaucoma, a leading cause of vision loss. Research reviews NTF roles in glaucoma pathogenesis and potential therapeutic delivery strategies for neuroprotection.
Area of Science:
- Ophthalmology
- Neuroscience
- Regenerative Medicine
Background:
- Glaucoma is a progressive optic neuropathy causing significant visual impairment globally.
- Retinal ganglion cell (RGC) degeneration is a hallmark of glaucoma.
- Neuroprotective therapies targeting RGCs are crucial for glaucoma treatment.
Purpose of the Study:
- To review the role of neurotrophic factor (NTF) deprivation and dysfunction in glaucoma pathogenesis.
- To summarize experimental evidence supporting NTF supplementation for neuroprotection in glaucoma animal models.
- To discuss clinical translation challenges and promising NTF delivery strategies for glaucoma.
Main Methods:
- Critical review of existing literature on NTFs in glaucoma.
- Analysis of experimental data from animal models of glaucoma.
- Evaluation of NTF delivery methods, including slow-release, gene therapy, and cell transplantation.
Main Results:
- Evidence suggests NTF deprivation/dysfunction contributes to glaucoma.
- Brain-derived neurotrophic factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor show neuroprotective potential in models.
- Various delivery strategies show promise but face clinical translation hurdles.
Conclusions:
- NTFs represent a promising therapeutic avenue for glaucoma.
- Further research into optimized NTF delivery is needed for clinical application.
- Targeting NTF pathways could preserve vision in glaucoma patients.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...